An open label, multi-center Phase 2 study in which the pharmacokinetics, safety, tolerability and efficacy of TH-4000 will be assessed in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
Hypoxia PET scans will be obtained in select centers to analyze potential predictors of tumor response.
